10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held on June 4, 2026. The meeting was conducted via live webcast to address governance matters including director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Approximately 90.5% of eligible votes were present or represented by proxy, constituting a quorum. The following matters were approved:
- Proposal 1 (Election of Directors): Stockholders elected three Class I directors (Serge Saxonov, Benjamin J. Hindson, John R. Stuelpnagel) to three-year terms expiring in 2029. While approved, the vote for John R. Stuelpnagel received the highest number of "Against" votes (24,072,179) among the nominees.
- Proposal 2 (Auditor Ratification): Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Executive Compensation): Stockholders approved the non-binding advisory vote on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Investor Verification Checklist
- Verify the specific reasons for the elevated "Against" votes (approx. 13.5%) for director nominee John R. Stuelpnagel compared to other nominees.
- Review the definitive proxy statement filed on April 24, 2026, for details on the executive compensation package approved in Proposal 3.
- Confirm the total number of eligible votes (219,700,782) against the company's current share count to ensure accuracy of the quorum calculation.